Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service carotid revascularization cases in New Mexico: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (200 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 171 | 40% |
| 2020 | 1 | 90 | 43% |
| 2021 | 2 | 72 | 46% |
| 2022 | 1 | 94 | 50% |
| 2023 | 1 | 119 | 53% |
| 2024 | 1 | 111 | 54% |
| 2025 from claims | – | 143 115–168 | 54% |
| 2026 forecast | – | 144 113–181 | 55% |
| 2027 forecast | – | 146 109–193 | 55% |
| 2028 forecast | – | 149 105–205 | 56% |
| 2029 forecast | – | 151 103–217 | 56% |
| 2030 forecast | – | 154 101–228 | 56% |
Carotid endarterectomy and stenting including TCAR. Professional codes (what the surgeon bills): CPT 35301, 37215.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Mexico; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 46 | 2,550−2.4%/yr | −2.4%/yr | 0.7 | 0% | 2,560 in 2030+0.1%/yr |
| Arizona | 21 | 884−3%/yr | −3%/yr | 1.2 | 0% | 1,070 in 2030+3.3%/yr |
| Washington | 15 | 658−6.5%/yr | −6.5%/yr | 0.8 | 0% | 680 in 2030+0.6%/yr |
| Oregon | 8 | 425−4.9%/yr | −4.9%/yr | 1.0 | 0% | 460 in 2030+1.4%/yr |
| Nevada | 11 | 315−0.4%/yr | −0.4%/yr | 1.1 | 0% | 610 in 2030+11%/yr |
| Colorado | 5 | 302−7.5%/yr | −7.5%/yr | 0.6 | 0% | 280 in 2030−1.5%/yr |
| Idaho | 7 | 243+15%/yr | +15%/yr | 1.2 | 0% | 590 in 2030+16%/yr |
| Utah | 2 | 170−2.8%/yr | −2.8%/yr | 0.8 | 0% | 110 in 2030−6.4%/yr |
| Montana | 4 | 162−1.2%/yr | −1.2%/yr | 0.8 | 0% | 170 in 2030+1.3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 8 | 925−4.6%/yr | −4.6%/yr | 3.80.7× | 96% | 850 in 2030−1.4%/yr |
| Dialysis access | 7 | 658−16%/yr | −16%/yr | 3.00.6× | 83% | 1,090 in 2030+8.7%/yr |
| Peripheral arterial intervention | 3 | 559−14%/yr | −14%/yr | 2.30.5× | 9% | 460 in 2030−3.1%/yr |
| Thrombectomy, IVC filters & venous stents | 1 | 215+4.7%/yr | +4.7%/yr | 0.90.8× | 0% | 60 in 2030−18%/yr |
Carotid revascularization in every state, and its device makers · Every procedure market in New Mexico · Every state · Compare with California
Medtronic leads with 55% of company spending on these surgeons in 2025, +55 pts on 2024.
In 2025, 2 companies reported engagement with New Mexico’s surgeons worth $383 in consulting, speaking, meals and travel tied to these products, about $383 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 19 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.